Compare VEON & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VEON | TVTX |
|---|---|---|
| Founded | 1992 | N/A |
| Country | United Arab Emirates | United States |
| Employees | 18938 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.3B |
| IPO Year | 2010 | 2013 |
| Metric | VEON | TVTX |
|---|---|---|
| Price | $76.76 | $55.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | ★ $86.87 | $75.21 |
| AVG Volume (30 Days) | 157.5K | ★ 1.4M |
| Earning Date | 11-06-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.96 | $47.65 |
| Revenue Next Year | $8.09 | $49.39 |
| P/E Ratio | $6.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.60 | $22.59 |
| 52 Week High | $77.49 | $68.73 |
| Indicator | VEON | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 73.81 | 33.71 |
| Support Level | $50.12 | $53.76 |
| Resistance Level | N/A | $59.93 |
| Average True Range (ATR) | 2.70 | 2.42 |
| MACD | 0.29 | -0.78 |
| Stochastic Oscillator | 95.33 | 6.64 |
VEON Ltd is a United Arab Emirates-based digital operator providing connectivity and Internet services to corporations and individuals. The company offers mobile and fixed-line telecommunications services through a range of traditional and broadband mobile technologies. The company's reportable segments consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. It provides its services under the Beeline, Kyivstar, Banglalink, and Jazz brands. It generates the majority of its revenue from Pakistan. Its telecommunications and digital services include voice, fixed broadband, data and cloud services.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.